Investigation of dissolution behavior of diclofenac sodium extended release formulations under standard and biorelevant test conditions

Drug Development and Industrial Pharmacy

Volumn 36, Issue 5, 2010, Pages 518-530

  Garbacz, Grzegorz ^a   Weitschies, Werner ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Biorelevant dissolution testing; Diclofenac extended release tablets; Dissolution stress test; HPMC matrix tablet; PH change

Indexed keywords

DICLOFENAC; EXCIPIENT;

ARTICLE; CONTROLLED STUDY; DEVICE; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG SOLUBILITY; EXTENDED RELEASE FORMULATION; PH; TABLET FORMULATION;

CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DICLOFENAC; SOLUBILITY; STRESS, MECHANICAL; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 77952665527     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903311081     Document Type: Article

References (39)

1. Brogden RN, Heel RC, Pakes GE, Speight TM, Avery GS. (1980). Diclofenac sodium: A review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin. Drugs, 1: 24-48.
2. Lotsch J, Kettenmann B, Renner B, Drover D, Brune K, Geisslinger G, et al. (2000). Population pharmacokinetics of fast release oral diclofenac in healthy volunteers: Relation to pharmacodynamics in an experimental pain model. Pharm Res, 17: 77-84.
3. Small RE. (1989). Diclofenac sodium. Clin Pharm, 8: 545-58.
4. Ho H, Liu CH, Lin HM, Sheu MT. (2003). The development of matrix tablets for diclofenac sodium based on an empirical invitro and in-vivo correlation. Int J Pharm, 251: 67-78.
5. Sheu MT, Chou HL, Kao CC, Liu CH, Sokoloski TD. (1992). Dissolution of diclofenac sodium from matrix tablets. Int J Pharm, 85: 57-63.
6. Chuasuwan B, Binjesoh V, Polli JE, Zhang H, Amidon GL, Junginger HE, et al. (2008). Biowaiver monographs for immediate release solid oral dosage forms: Diclofenac sodium and diclofenac potassium. J Pharm Sci, 7: 5061-73.
7. Llinàs A, Burley JC, Box KJ, Glen RC, Goodman JM. (2007). Diclofenac solubility: Independent determination of the intrinsic solubility of three crystal forms. J Med Chem, 50: 979-83.
8. O'Connor KM, Corrigan OI. (2001). Preparation and characterisation of a range of diclofenac salts. Int J Pharm, 226: 163-79.
9. Sobhan MA, Granqvist CG, Kivaisi RT, Stjerna B, Arpesella C, Broggini C, et al. (1996). Factors governing the dissolution of diclofenac salts. Eur J Pharm Sci, 4: 231-8.
10. Garbacz G, Wedemeyer RS, Nagel S, Giessmann T, Mönnikes H, Wilson CG, et al. (2008). Irregular absorption profiles observed from diclofenac extended release tablets can be predicted using a dissolution test apparatus that mimics in-vivo physical stresses. Eur J Pharm Biopharm, 70: 421-8.
11. Riad LE, Sawchuk RJ, McAlary MM, Chan KK. (1995). Effect of food on the multiple peak behavior after a single oral dose of diclofenac sodium slow-release tablet in humans. Am J Ther, 2: 237-42.
12. Vidon N, Pfeiffer A, Godbillon J, Rongier M, Gauron S, Hirtz J, et al. (1989). Evaluation of the gastric absorption and emptying of drugs under various pH conditions using a simple intubation method: Application to diclofenac. Br J Clin Pharmacol, 28: 121-4.
13. Chan H, Mojaverian P, Ziehmer BA, John VA. (1990). Application of radiotelemetric technique in evaluating diclofenac sodium absorption after oral administration of various dosage forms in healthy volunteer. Pharm Res, 7: 1026-32.
14. Liu H, Kao YH, Chen SC, Sokoloski TD, Sheu MT. (1995). Invitro and in-vivo studies of diclofenac sodium controlledrelease matrix tablets. J Pharm Pharmacol, 47: 360-4.
15. Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. (1988). Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut, 29: 1035-41.
16. Krajacic A, Tucker IG. (2003). Matrix formation in sustained release tablets: Possible mechanism of dose dumping. Int J Pharm, 251: 67-78.
17. Weitschies W, Cordini D, Karaus M, Trahms L, Semmler W. (1999). Magnetic marker monitoring of the oesophageal, gastric and duodenal transit of nondisintegrating capsules. Pharmazie, 54: 426-30.
18. Weitschies W, Kosch O, Mönnikes H, Trahms L. (2005). Magnetic marker monitoring: An application of biomagnetic measurement instrumentation and principles for the determination of the gastrointestinal behavior of magnetically marked solid dosage forms. Adv Drug Deliv Rev, 57: 1210-22.
19. Cassilly D, Kantor S, Knight LC, Maurer AH, Fisher RS, Semler J, et al. (2008). Gastric emptying of a non-digestible solid: Assessment with simultaneous SmartPill pH and pressure capsule, antroduodenal manometry, gastric emptying scintigraphy. Neurogastroenterol Motil, 20: 311-9.
20. Dinning PG, Bampton PA, Kennedy ML, Kajimoto T, Lubowski DZ, de Carle DJ, et al. (1999). Basal pressure patterns and reflexive motor responses in the human ileocolonic junction. Am J Physiol, 276: G331-40.
21. Kamba M, Seta Y, Kusai A, Ikeda M, Nishimura K. (2000). A unique dosage form to evaluate the mechanical destructive force in the gastrointestinal tract. Int J Pharm 208: 61-70.
22. Schiller C, Frohlich CP, Giessman T, Siegmund W, Monnikes H, Hostein N, et al. (2005). Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacol Ther, 22: 971-79.
23. Pillay V, Fassihi R. (1998). Evaluation and comparison of dissolution data derived from different modified release dosage forms: An alternative method. J Control Release, 55: 45-55.
24. Committee for Proprietary Medicinal Products. (2001). Note for guidance on the investigation of bioavailability and bioequivalence CMP/EWP/QWP1401/98. EMEA, London.
25. Committee for Proprietary Medicinal Products. (2008). Guideline on the investigation of bioequivalence CPMP/EWP/QWP/1401/98 Rev. 1 EMEA, London.
26. Commission Regulation (EC). 2003. No 1084/2003, EMEA, London.
27. Henderson JD, Esham RH. (2001). Generic substitution: Issues for problematic drugs. South Med J, 94: 16-21.
28. Meredith P. (2003). Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther, 25: 2875-90.
29. Bai G, Armenante PM. (2009). Hydrodynamic, mass transfer, and dissolution effects induced by tablet location during dissolution testing. J Pharm Sci, 98: 1511-31.
30. McCarthy GL, Bradley G, Sexton JC, Corrigan OI, Healy AM. (2004). Computational fluid dynamics modeling of the paddle dissolution apparatus: Agitation rate, mixing patterns, and fluid velocities. AAPS PharmSciTech, 5: e31.
31. Bertocchia P, Antoniellaa E, Valvoa E, Alimontia S, Memolib A. (2005). Diclofenac sodium multisource prolonged release tablets-a comparative study on the dissolution profiles. J Pharm Biomed Anal, 37: 679-85.
32. Barreiro MA, McKenna RD, Beck IT. (1968). Determination of transit in the human jejunum by the single-injection indicatordilution technique. Am J Dig Dis, 13: 222-33.
33. Duthie HL. (1978). Colonic response to eating. Gastroenterology, 75: 527-8.
34. Spiller RC, Brown ML, Phillips SF. (1987). Emptying of the terminal ileum in intact humans. Influence of meal residue and ileal motility. Gastroenterology, 92: 724-9.
35. Bettini R, Catellani PL, Santi P, Massimo G, Peppas NA, Colombo P. (2001). Translocation of drug particles in HPMC matrix gel layer: Effect of drug solubility and influence on release rate. J Control Release, 70: 383-91.
36. Colombo P, Bettini R, Santi P, De Ascentiis A, Peppas NA. (1996). Analysis of the swelling and release mechanism from the drug delivery systems with emphasis on drug solubility and water transport. J Control Release, 39: 231-7.
37. Jantratid E, Janssen N, Reppas C, Dressman JB. (2008). Dissolution media simulating conditions in the proximal human gastrointestinal tract: An update. Pharm Res, 25: 1663-76.
38. Kalantzi L, Goumas K, Kalioras V, Abrahamsson B, Dressman JB, Reppas C. (2006). Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies. Pharm Res, 23: 165-76.
39. Zoeller T, Klein S. (2007). Simplified biorelevant media for screening dissolution performance of poorly soluble drugs. Dissol Technol, 14: 8-13.